[September 8, 2021] Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a four-year collaboration with the Bill & Melinda Gates Foundation, a non-profit focused on fighting global poverty, disease, and inequity, Read More
Exscientia plc is an artificial intelligence-driven pharmaceutical company focused on discovering, designing, and developing drugs in a fast, efficient manner, with three AI-designed drugs that are in Phase 1 human clinical trials. The foundation invested in the Company to develop Read More
Atreca is a biotechnology company that employs its proprietary discovery platform to generate and develop therapeutics based on its ability to rapidly characterize the human adaptive immune response at the single cell level. The Atreca platform enables the high-throughput phylogenetic Read More
May 24, 2019 Atreca, a preclinical biotech developing immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Redwood City, CA-based company was founded in 2010 and plans Read More
By Conor Hale May 9, 2018 Genentech signed a broad, open-ended drug discovery collaboration with Lodo Therapeutics that could be worth nearly $1 billion, focused on deriving unique, natural products from the microbial DNA found in soil. The drugmaker plans Read More
April 26, 2018 SOUTH SAN FRANCISCO, Calif., April 26, 2018 (GLOBE NEWSWIRE) — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has entered into an award agreement with Read More
Visterra is a biotechnology company that uses its proprietary platform to identify unique disease targets and design and engineer effective biological therapeutics.
Sera Prognostics, based in Salt Lake City, UT, is developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications.
Lodo Therapeutics is creating a best-in-class natural product drug discovery platform for the discovery, biosynthesis, and characterization of new, genetically encoded small molecules.
Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.